New Key Statistics Module, Z-Score and F-Score
NAS:CPRX Key Ratios
| Market Cap $ M | 3,854.93 |
| Enterprise Value $ M | 3,101.75 |
| P/E(ttm) | 18.10 |
| PE Ratio without NRI | 15.66 |
| Forward PE Ratio | 16.12 |
| Price/Book | 3.80 |
| Price/Sales | 6.71 |
| Price/Free Cash Flow | 19.26 |
| Price/Owner Earnings | 25.64 |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | 596.00 |
| EPS (TTM) $ | 1.74 |
| Beneish M-Score | -1.84 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | 45.30 |
| y-y EBITDA Growth Rate % | 12.40 |
| EV-to-EBIT | 11.59 |
| EV-to-EBITDA | 10.14 |
| PEG | 0.35 |
| Shares Outstanding M | 122.42 |
| Net Margin (%) | 37.08 |
| Operating Margin % | 44.83 |
| Pre-tax Margin (%) | 49.66 |
| Quick Ratio | 6.84 |
| Current Ratio | 7.10 |
| ROA % (ttm) | 21.35 |
| ROE % (ttm) | 24.39 |
| ROIC % (ttm) | 81.33 |
| Dividend Yield % | -- |
| Altman Z-Score | 20.00 |
CPRX Number of Guru Trades
CPRX Volume of Guru Trades
Gurus Latest Trades with NAS:CPRX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NAS:CPRX is held by these investors
Total 3
Catalyst Pharmaceuticals Inc Insider Transactions
No Available Data
Guru Commentaries on NAS:CPRX
2026 Q1
What the manager wrote
Catalyst Pharmaceuticals, Inc. has achieved long-running profitability and boasts a sizeable and growing cash balance. The company employs an owner-operator approach through its buy-and-build strategy, focusing on acquiring orphan-designated assets from smaller biotech firms. This model supports the launch of significantly derisked products. Catalyst's primary growth driver is Firdapse, the only approved drug in the U.S. for treating LEMS, which has substantial growth potential over the next nine years. The company is also working to expand its patient population and grow revenues at a mid-teens rate.
News about NAS:CPRX
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers